Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Kiniksa Pharmaceuticals International EV-to-FCF?
Kiniksa Pharmaceuticals InternationalKNSA +4.73%50 EV-to-FCF is 27.16 as of Jul. 18, 2026, which is 9% above its 10-year median of 24.85. GuruFocus rates KNSA with a GF Score™ of 50/100 and a GF Value™ of $48.69 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 564 Drug Manufacturers companies, Kiniksa Pharmaceuticals International ranks worse than 55.14% on this metric.
KNSA'
s EV-to-FCF Range Over the Past 10 Years
Min: -560.55 Med: 24.85 Max: 160.78
Current: 27.16
During the past 10 years, the highest EV-to-FCF of Kiniksa Pharmaceuticals International was 160.78. The lowest was -560.55. And the median was 24.85.
KNSA's EV-to-FCF is ranked worse than 55.14% of 564
companies
in the Drug Manufacturers industry
Industry Median: 20.815
vs KNSA: 27.16
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Kiniksa Pharmaceuticals International (NAS:KNSA) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Kiniksa Pharmaceuticals International's PE Ratio (TTM) for today is calculated as:
Kiniksa Pharmaceuticals International's share price for today is $63.93.
Kiniksa Pharmaceuticals International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.900.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Kiniksa Pharmaceuticals International EV-to-FCF Related Terms
Kiniksa Pharmaceuticals International EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiniksa Pharmaceuticals International EV-to-FCF Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Kiniksa Pharmaceuticals International's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kiniksa Pharmaceuticals International EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kiniksa Pharmaceuticals International's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Kiniksa Pharmaceuticals International's EV-to-FCF falls into.
Kiniksa Pharmaceuticals International's current Enterprise Value is $4,461.1 Mil.
Kiniksa Pharmaceuticals International's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $164.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiniksa Pharmaceuticals International (KNSA) has a EV-to-FCF of 27.16 as of Jul. 18, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Kiniksa Pharmaceuticals International and its competitors. This is near median its historical median of 24.85. According to the industry distribution chart, Kiniksa Pharmaceuticals International ranks #311 out of 564 companies in the Drug Manufacturers industry, placing it in the top 55.1%.
Is Kiniksa Pharmaceuticals International's EV-to-FCF too high?
Kiniksa Pharmaceuticals International's current EV-to-FCF of 27.16 is near median its 10-year median of 24.85. The Drug Manufacturers industry median EV-to-FCF is 20.82. Kiniksa Pharmaceuticals International's value of 27.16 is 30.5% above this industry median. Based on the distribution chart, Kiniksa Pharmaceuticals International ranks #311 out of 564 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Kiniksa Pharmaceuticals International has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kiniksa Pharmaceuticals International's EV-to-FCF compare to INDV and AMRX?
According to the Drug Manufacturers industry distribution chart, Kiniksa Pharmaceuticals International ranks #311 out of 564 companies for EV-to-FCF. This places Kiniksa Pharmaceuticals International in the lower half of its industry. The industry median EV-to-FCF is 20.82. Kiniksa Pharmaceuticals International's value of 27.16 is 30.5% above this benchmark. While the company's 10-year median is 24.85 vs. the industry median of 20.82, Kiniksa Pharmaceuticals International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.82, based on 564 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kiniksa Pharmaceuticals International's current EV-to-FCF of 27.16 is 30.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Kiniksa Pharmaceuticals International and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kiniksa Pharmaceuticals International's current EV-to-FCF is 27.16, which is near median its own 10-year median of 24.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiniksa Pharmaceuticals International stock overvalued right now?
Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International (KNSA) is currently considered Significantly Overvalued. The stock's GF Value™ is $48.69, compared to a current price of $63.93 — trading 31.3% above its estimated fair value. The current EV-to-FCF is 27.16, which is near median its 10-year median of 24.85 and 30.5% above the Drug Manufacturers industry median of 20.82. Kiniksa Pharmaceuticals International's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Kiniksa Pharmaceuticals International (KNSA), the current EV-to-FCF is 27.16 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kiniksa Pharmaceuticals International (KNSA) Overvalued in 2026?
Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International stock appears to be overvalued.
The current stock price of $63.93 is trading 31.3% above its estimated GF Value™ of $48.69.
GuruFocus considers Kiniksa Pharmaceuticals International to be Significantly Overvalued.
Key valuation signals for KNSA:
EV-to-FCF: 27.16 (near median its 10-year median of 24.85)
GF Value™: $48.69 vs. price of $63.93 (31.3% above fair value)
Industry Position: 30.5% above the Drug Manufacturers median (#311 of 564)
No single metric tells the full story. See the KNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kiniksa Pharmaceuticals International Business Description
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
50GF Score
Get the complete analysis for KNSA
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNSA has been successfully added to your 
